open access to scientific and medical research

Back to Journals » ClinicoEconomics and Outcomes Research » Volume 11

Original Research

Noteworthy comment: This study assessed different methods to determine whether high ICERs (incremental cost-effectiveness ratio) are caused by high drug costs, high ‘background costs’ or a combination of both and how different approaches can alter the impact of background costs on the ICER where the marginal cost-effectiveness ratio is close to, or above, the cost-effectiveness threshold.

Highly-accessed

The impact of increased post-progression survival on the cost-effectiveness of interventions in oncology

Total article views		HTML views	PDF downloads	Totals
7,004	Dovepress*	5,909+	1,523	7,432
	PubMed Central*	1,095	220	1,315
	Totals	7,004	1,743	8,747
*Since 3 May 2019

View citations on PubMed Central and Google Scholar